Vistagen Therapeutics, Inc. (VTGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on November 28, 2025, by Vistagen Therapeutics, Inc., a Nevada corporation. The report discloses the appointment of a new Chief Financial Officer and Treasurer, effective December 1, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Executive Appointment: Nick B. Tressler was appointed as Chief Financial Officer, Treasurer, and principal financial and accounting officer, effective December 1, 2025.
- Role Transition: Shawn K. Singh, President and CEO, will no longer serve as the interim principal financial and accounting officer.
- Compensation Package:
- Annual Base Salary: $450,000.
- Signing Bonus: $50,000.
- Annual Discretionary Cash Bonus: Target of 45% of base salary.
- Equity Grant: 150,000 stock options (Inducement Grant) with an exercise price of $4.43 per share.
- Vesting Schedule: Begins one year after the effective date; vests monthly over 36 months (fully vested on the fourth anniversary).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of operational risks. It notes the execution of an Indemnification Agreement to protect Mr. Tressler against liabilities arising from his service to the company. The stock option grant was issued in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement material to entering employment.
Key Facts for Investor Verification
- Verify the impact of the new CFO's appointment on the company's financial reporting and strategic direction.
- Confirm the dilution impact of the 150,000 share option grant on existing shareholders.
- Review the full text of the Indemnification Agreement (Exhibit 10.1) for specific liability protections.
- Monitor future filings for the first financial statements prepared under the new CFO's oversight.